$DSS
DSS, INC. Stock $dss

$dss Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031643 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$5.599M	$4.211M	$7.233M
YoY Change	33.88%	-41.78%	-38.55%
Cost Of Revenue		$5.673M	$4.832M
YoY Change		17.4%	-37.0%
Gross Profit		-$1.462M	$2.401M
YoY Change		-160.89%	-41.45%
Gross Profit Margin		-34.72%	33.2%
Selling, General & Admin	$3.667M	$3.473M	$8.851M
YoY Change	14.13%	-60.76%	-42.09%
% of Gross Profit			368.64%
Research & Development		$0.00	$266.0K
YoY Change		-100.0%	29.13%
% of Gross Profit			11.08%
Depreciation & Amortization		$554.0K	$1.314M
YoY Change		-57.84%	-58.4%
% of Gross Profit			54.73%
Operating Expenses	$10.27M	$9.146M	$13.68M
YoY Change	10.61%	-33.16%	-40.39%
Operating Profit	-$4.671M	-$4.935M	-$6.450M
YoY Change	-8.47%	-23.49%	-42.32%
Interest Expense	$53.00K	$142.0K	$138.0K
YoY Change	3.92%	2.9%	14.05%
% of Operating Profit
Other Income/Expense, Net	$2.000K	$12.00K	$147.0K
YoY Change	-104.55%	-91.84%	-93.73%
Pretax Income	-$5.701M	-$5.142M	-$37.72M
YoY Change	-14.67%	-86.37%	597.28%
Income Tax		-$188.0K
% Of Pretax Income
Net Earnings	-$5.283M	-$4.683M	-$37.92M
YoY Change	21.67%	-87.65%	715.2%
Net Earnings / Revenue	-94.36%	-111.21%	-524.31%
Basic Earnings Per Share	-$0.75	-$0.66	-$0.27
Diluted Earnings Per Share	-$0.75	-$0.66	-$0.27
COMMON SHARES
Basic Shares Outstanding	7.067M shares	7.067M shares	140.3M shares
Diluted Shares Outstanding	7.067M shares	7.067M shares	140.1M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$10.72M	$10.18M
YoY Change		5.28%	-76.83%
Cash & Equivalents	$11.60M	$10.70M	$10.03M
Short-Term Investments			$148.0K
Other Short-Term Assets		$46.97M	$2.723M
YoY Change		1624.9%	26.12%
Inventory	$3.307M	$3.572M	$5.300M
Prepaid Expenses
Receivables	$2.653M	$2.531M	$2.468M
Other Receivables		$3.907M	$9.269M
Total Short-Term Assets	$68.81M	$67.70M	$29.79M
YoY Change	181.96%	127.23%	-60.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.860M	$6.054M	$12.44M
YoY Change	-52.55%	-51.33%	-22.28%
Goodwill	$26.86M	$26.86M	$57.88M
YoY Change	-53.59%	-53.59%	2.25%
Intangibles
YoY Change
Long-Term Investments	$131.0K	$135.0K	$139.0K
YoY Change	-2.24%	-2.88%	-85.85%
Other Assets	$133.0K	$139.0K	$261.0K
YoY Change	-45.93%	-46.74%	-67.42%
Total Long-Term Assets	$73.85M	$76.75M	$175.1M
YoY Change	-57.1%	-56.16%	-15.89%
TOTAL ASSETS
Total Short-Term Assets	$68.81M	$67.70M	$29.79M
Total Long-Term Assets	$73.85M	$76.75M	$175.1M
Total Assets	$142.7M	$144.4M	$204.9M
YoY Change	-27.42%	-29.49%	-27.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.399M	$3.430M	$3.046M
YoY Change	16.24%	12.61%	44.22%
Accrued Expenses		$2.650M	$3.713M
YoY Change		-28.63%	-70.26%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due	$49.87M	$49.13M	$47.21M
YoY Change	6.94%	4.08%	1.06%
Total Short-Term Liabilities	$59.08M	$57.67M	$55.49M
YoY Change	10.49%	3.92%	-10.08%
LONG-TERM LIABILITIES
Long-Term Debt	$7.443M	$7.029M	$7.218M
YoY Change	-3.92%	-2.62%	-63.11%
Other Long-Term Liabilities		$6.603M	$507.0K
YoY Change		1202.37%	0.0%
Total Long-Term Liabilities	$7.443M	$7.029M	$7.725M
YoY Change	-9.83%	-9.01%	-61.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.08M	$57.67M	$55.49M
Total Long-Term Liabilities	$7.443M	$7.029M	$7.725M
Total Liabilities	$72.98M	$64.70M	$63.22M
YoY Change	18.23%	2.34%	-22.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$270.2M	-$264.9M	-$221.5M
YoY Change	19.63%	19.59%	50.49%
Common Stock	$141.0K	$140.0K	$2.804M
YoY Change	-94.97%	-95.01%	40.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$52.12M	$55.17M	$98.64M
YoY Change
Total Liabilities & Shareholders Equity	$142.7M	$144.4M	$204.9M
YoY Change	-27.42%	-29.49%	-27.6%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$5.283M	-$4.683M	-$37.92M
YoY Change	21.67%	-87.65%	715.2%
Depreciation, Depletion And Amortization		$554.0K	$1.314M
YoY Change		-57.84%	-58.4%
Cash From Operating Activities		-$3.424M	-$5.516M
YoY Change		-37.93%	-29.97%
INVESTING ACTIVITIES
Capital Expenditures		$26.00K	-$98.00K
YoY Change		-126.53%	188.24%
Acquisitions
YoY Change
Other Investing Activities		$3.705M	$1.741M
YoY Change		112.81%	-270.85%
Cash From Investing Activities		$3.679M	$1.839M
YoY Change		100.05%	-274.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.212M	-22.00K
YoY Change		-5609.09%	-97.65%
NET CHANGE
Cash From Operating Activities		-3.424M	-5.516M
Cash From Investing Activities		3.679M	1.839M
Cash From Financing Activities		1.212M	-22.00K
Net Change In Cash		1.467M	-3.699M
YoY Change		-139.66%	-62.51%
FREE CASH FLOW
Cash From Operating Activities		-$3.424M	-$5.516M
Capital Expenditures		$26.00K	-$98.00K
Free Cash Flow		-$3.450M	-$5.418M
YoY Change		-36.32%	-30.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32146
	dei	Entity Registrant Name EntityRegistrantName	DSS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NY
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	16-1229730
	dei	Entity Address Address Line1 EntityAddressAddressLine1	275 Wiregrass Pkwy
	dei	Entity Address City Or Town EntityAddressCityOrTown	West Henrietta
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	14586
	dei	City Area Code CityAreaCode	(585)
	dei	Local Phone Number LocalPhoneNumber	325-3610
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3473000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000771999
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, $0.02 par value per share
	dei	Trading Symbol TradingSymbol	DSS
	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7066772	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	319963000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-264930000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	55173000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73150000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	144448000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Dividend Income Operating DividendIncomeOperating		usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2023Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
	DSS	Payments For Proceeds From Investments Excluding Notes Receivables PaymentsForProceedsFromInvestmentsExcludingNotesReceivables		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations		usd
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.02
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6615000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3994000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2819000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	51595000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	8772000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	839000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	74634000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6417000	usd
CY2023Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	6279000	usd
CY2023Q4	us-gaap	Other Investments OtherInvestments	1282000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	128000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	9979000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	111000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	97000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7210000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	26862000	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	20193000	usd
CY2023Q4	us-gaap	Assets Assets	153192000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3654000	usd
CY2023Q4	DSS	Accrued Expenses And Deferred Revenue Current AccruedExpensesAndDeferredRevenueCurrent	2512000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	983000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	686000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	47776000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55611000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7451000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6917000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.02
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	47000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2024Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.02
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7066772	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7066772	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7066772	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7066772	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	140000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	140000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	319963000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256176000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	63927000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	17977000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	19286000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	83213000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153192000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4211000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7233000	usd
CY2024Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5673000	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4832000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8851000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	9146000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	13683000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4935000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6450000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	195000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	407000	usd
CY2023Q2	us-gaap	Dividend Income Operating DividendIncomeOperating	8000	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	12000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	147000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	142000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	138000	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9000	usd
CY2024Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8000	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-18000	usd
CY2024Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-383000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-27922000	usd
CY2024Q2	DSS	Provision For Loan Losses ProvisionForLoanLosses	-53000	usd
CY2023Q2	DSS	Provision For Loan Losses ProvisionForLoanLosses	-3757000	usd
	DSS	Provision For Loan Losses ProvisionForLoanLosses	-346000	usd
	DSS	Provision For Loan Losses ProvisionForLoanLosses	-3757000	usd
CY2024Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	165000	usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	165000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5142000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37723000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10226000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46357000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-188000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4954000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-37723000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10063000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-46357000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-271000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	200000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1309000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-398000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-4683000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-37923000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8754000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45959000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.59
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.59
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7066772	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7007046	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7066772	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6978952	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7066772	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7007046	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7066772	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6978952	shares
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10063000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-46357000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1136000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2647000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	268000	usd
	DSS	Equity Method Investments Gain Loss EquityMethodInvestmentsGainLoss	7000	usd
	DSS	Equity Method Investments Gain Loss EquityMethodInvestmentsGainLoss	-22000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-572000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-30790000	usd
	DSS	Change In Right Of Use Assets ChangeInRightOfUseAssets	-369000	usd
	DSS	Change In Right Of Use Assets ChangeInRightOfUseAssets	-774000	usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	165000	usd
	DSS	Impairment Of Notes Receivable ImpairmentOfNotesReceivable	815000	usd
	DSS	Impairment Of Notes Receivable ImpairmentOfNotesReceivable	3757000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1679000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2531000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	753000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4707000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-504000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-592000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	42000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3123000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-224000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3846000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-529000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15958000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-339000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1052000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1473000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-81000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5574000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18083000	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1632000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5574000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19715000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	496000	usd
	DSS	Payments For Proceeds From Investments Excluding Notes Receivables PaymentsForProceedsFromInvestmentsExcludingNotesReceivables	379000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5140000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	215000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11330000	usd
	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	4044000	usd
	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	2327000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8776000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13376000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1269000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5519000	usd
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	2171000	usd
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	2601000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	902000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2918000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations	4104000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations	-7625000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations	-1632000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6615000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19290000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10719000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10033000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156681000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	268000	usd
	DSS	Deconsolidation Of Sharing Services Global Corporation DeconsolidationOfSharingServicesGlobalCorporation	23837000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-46357000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	134429000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	83213000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10063000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73150000	usd
CY2023Q2	DSS	Deconsolidation On Loss Before Income Taxes DeconsolidationOnLossBeforeIncomeTaxes	29196000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zeRZPWUUfJWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zVAaQUeqfjhh">Use of Estimates</span> - </i></b>The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill, useful lives of intangible assets and property and equipment, fair values of options and warrants to purchase the Company’s common stock, preferred stock, deferred revenue and income taxes, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2500000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2494000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zUKKAQXd0s6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zUnU2dga1Kzk">Concentration of Credit Risk</span></i></b> - The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company believes it is not exposed to any significant credit risk because of any non-performance by the financial institutions. As of June 30, 2024, one customers accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcwTJmSq6BH8" title="Concentration Risk, Percentage">24</span>% of our consolidated revenue and one customers accounted for approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGaAY9Dvm2kc" title="Concentration Risk, Percentage">39</span>% of our trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, two customers accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztTtQb9N9a4h" title="Concentration Risk, Percentage">19</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zaTUasxAdC1e" title="Concentration Risk, Percentage">5</span>% of our consolidated revenue and these two customers accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpdNWh1j3j65" title="Concentration Risk, Percentage">55</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3n129oHZOdl" title="Concentration Risk, Percentage">14</span>% of our consolidated trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, two customers accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfL1TEPLB9b4" title="Concentration Risk, Percentage">20</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhZwoYVF65cf" title="Concentration Risk, Percentage">11</span>% of our consolidated revenue and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZBZhsgXaA26">39</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWb6aWMBkWJc">30</span>% of our trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended of June 30, 2024 one vendor accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0WYnskaj15h" title="Concentration risk, percentage">12</span>% of our cost of revenue and for the six months ended June 30, 2023, another vendor accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfzAS2VYnYz7" title="Concentration risk, percentage">14</span>% of our cost of revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Other Assets OtherAssets	65000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7418000	usd
CY2024Q2	us-gaap	Cash Cash	10700000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10700000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9600000	usd
CY2024Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	46000000.0	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2592000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2218000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	173000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	180000	usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	837000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	439000	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	3602000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	2837000	usd
CY2024Q2	us-gaap	Inventory Adjustments InventoryAdjustments	30000	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	18000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	3572000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2819000	usd
	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	37703000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-17426000	usd
CY2024Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	20277000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	10719000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9558000	usd
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	33919000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-17325000	usd
CY2023Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	16594000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6615000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9979000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	49130000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	831000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	902000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	948000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	996000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3352000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	479000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	860000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	839000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	808000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	824000	usd
CY2024Q2	DSS	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	4913000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8723000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1459000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	7264000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	661000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6603000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041	pure
	DSS	Cash Paid For Leases CashPaidForLeases	498000	usd
	DSS	Cash Paid For Leases CashPaidForLeases	513000	usd
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 20
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	On May 10, 2023, the Company, the Company’s Board of Directors approved an amendment to the Articles of Incorporation of the Company to increase the total number of shares of Common Stock to 4,000,000,000 shares with a par value of $0.001. Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation also authorized 100,000,000 shares of preferred stock, par value $0.001 per share. On May 11, 2023, the Company effected a forward split. As a result, there were 3,877,282,251 shares of our Common Stock and no shares of preferred stock issued and outstanding. Prior to the split, there were 125,073,621 shares of our Common Stock and no shares of preferred stock issued and outstanding. On October 31, 2023, the Company effected a reverse stock split of 1 for 55. Also on October 31, 2023, DSS BioHealth Securities, Inc., the Company’s largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing its ownership of the Company’s Common Stock from approximately 88% to approximately 12%. As of June 30, 2024 and December 31, 2023, there were 10,000,000 shares of our Common Stock and 60,496,041 shares of preferred stock issued and outstanding
	us-gaap	Interest Paid Net InterestPaidNet	501000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1402000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	5	segments

Files In Submission

Name	View Source	Status
dss-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-24-031643-index-headers.html	Edgar Link	pending
0001493152-24-031643-index.html	Edgar Link	pending
0001493152-24-031643.txt	Edgar Link	pending
0001493152-24-031643-xbrl.zip	Edgar Link	pending
dss-20240630.xsd	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
ex10-1_002.jpg	Edgar Link	pending
ex10-1_003.jpg	Edgar Link	pending
ex10-1_004.jpg	Edgar Link	pending
ex10-1_005.jpg	Edgar Link	pending
ex10-1_006.jpg	Edgar Link	pending
ex10-1_007.jpg	Edgar Link	pending
ex10-1_008.jpg	Edgar Link	pending
ex10-1_009.jpg	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex10-2_001.jpg	Edgar Link	pending
ex10-2_002.jpg	Edgar Link	pending
ex10-2_003.jpg	Edgar Link	pending
ex10-2_004.jpg	Edgar Link	pending
ex10-2_005.jpg	Edgar Link	pending
ex10-2_006.jpg	Edgar Link	pending
ex10-2_007.jpg	Edgar Link	pending
ex10-2_008.jpg	Edgar Link	pending
ex10-2_009.jpg	Edgar Link	pending
ex10-2_010.jpg	Edgar Link	pending
ex10-2_011.jpg	Edgar Link	pending
ex10-2_012.jpg	Edgar Link	pending
ex10-2_013.jpg	Edgar Link	pending
ex10-2_014.jpg	Edgar Link	pending
ex10-2_015.jpg	Edgar Link	pending
ex10-2_016.jpg	Edgar Link	pending
ex10-2_017.jpg	Edgar Link	pending
ex10-2_018.jpg	Edgar Link	pending
ex10-2_019.jpg	Edgar Link	pending
ex10-2_020.jpg	Edgar Link	pending
ex10-2_021.jpg	Edgar Link	pending
ex10-2_022.jpg	Edgar Link	pending
ex10-2_023.jpg	Edgar Link	pending
ex10-2_024.jpg	Edgar Link	pending
ex10-2_025.jpg	Edgar Link	pending
ex10-2_026.jpg	Edgar Link	pending
ex10-2_027.jpg	Edgar Link	pending
ex10-2_028.jpg	Edgar Link	pending
ex10-2_029.jpg	Edgar Link	pending
ex10-2_030.jpg	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
dss-20240630_def.xml	Edgar Link	unprocessable
dss-20240630_lab.xml	Edgar Link	unprocessable
dss-20240630_pre.xml	Edgar Link	unprocessable
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
ex3-1_004.jpg	Edgar Link	pending
ex3-1_005.jpg	Edgar Link	pending
ex3-1_006.jpg	Edgar Link	pending
ex3-1_007.jpg	Edgar Link	pending
ex3-1_008.jpg	Edgar Link	pending
ex3-1_009.jpg	Edgar Link	pending
ex3-1_010.jpg	Edgar Link	pending
ex3-1_011.jpg	Edgar Link	pending
ex3-1_012.jpg	Edgar Link	pending
ex3-1_013.jpg	Edgar Link	pending
ex3-1_014.jpg	Edgar Link	pending
ex3-1_015.jpg	Edgar Link	pending
ex3-1_016.jpg	Edgar Link	pending
ex3-1_017.jpg	Edgar Link	pending
ex3-1_018.jpg	Edgar Link	pending
ex3-1_019.jpg	Edgar Link	pending
ex3-1_020.jpg	Edgar Link	pending
ex3-1_021.jpg	Edgar Link	pending
ex3-1_022.jpg	Edgar Link	pending
ex3-1_023.jpg	Edgar Link	pending
ex3-1_024.jpg	Edgar Link	pending
ex3-1_025.jpg	Edgar Link	pending
ex3-1_026.jpg	Edgar Link	pending
ex3-1_027.jpg	Edgar Link	pending
ex3-1_028.jpg	Edgar Link	pending
ex3-1_029.jpg	Edgar Link	pending
ex3-1_030.jpg	Edgar Link	pending
ex3-1_031.jpg	Edgar Link	pending
ex3-1_032.jpg	Edgar Link	pending
ex3-1_033.jpg	Edgar Link	pending
ex3-1_034.jpg	Edgar Link	pending
ex3-1_035.jpg	Edgar Link	pending
ex3-1_036.jpg	Edgar Link	pending
ex3-1_037.jpg	Edgar Link	pending
ex3-1_038.jpg	Edgar Link	pending
ex3-1_039.jpg	Edgar Link	pending
ex3-1_040.jpg	Edgar Link	pending
ex3-1_041.jpg	Edgar Link	pending
ex3-1_042.jpg	Edgar Link	pending
ex3-1_043.jpg	Edgar Link	pending
ex3-1_044.jpg	Edgar Link	pending
ex3-1_045.jpg	Edgar Link	pending
ex3-1_046.jpg	Edgar Link	pending
ex3-1_047.jpg	Edgar Link	pending
ex3-1_048.jpg	Edgar Link	pending
ex3-1_049.jpg	Edgar Link	pending
ex3-1_050.jpg	Edgar Link	pending
ex3-1_051.jpg	Edgar Link	pending
ex3-1_052.jpg	Edgar Link	pending
ex3-1_053.jpg	Edgar Link	pending
ex3-1_054.jpg	Edgar Link	pending
ex3-1_055.jpg	Edgar Link	pending
ex3-1_056.jpg	Edgar Link	pending
ex3-1_057.jpg	Edgar Link	pending
ex3-1_058.jpg	Edgar Link	pending
ex3-1_059.jpg	Edgar Link	pending
ex3-1_060.jpg	Edgar Link	pending
ex3-1_061.jpg	Edgar Link	pending
ex3-1_062.jpg	Edgar Link	pending
ex3-1_063.jpg	Edgar Link	pending
ex3-2.htm	Edgar Link	pending
ex3-3.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DSS
DSS, INC. Stock $dss

2024 Q3 Form 10-Q Financial Statement

#000149315224031643 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DSS DSS, INC. Stock $dss

2024 Q3 Form 10-Q Financial Statement

#000149315224031643 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DSS
DSS, INC. Stock $dss